A new paper published in The Lancet Psychiatry sets out principles for responsibly testing innovative treatments for severe depression, based on treating more than 100 patients with approximately 1,000 infusions of ketamine over six years in Oxford.
Shutterstock
Image courtesy of Shutterstock
Ketamine is known to be an effective antidepressant for people whose depression has not responded to other treatment.
The paper highlights the need for ethical and innovative professional action by setting out key qualities of the responsible clinician in providing ketamine treatment.
